FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379328966> ?p ?o ?g. }

• W4379328966 endingPage "1029" @default.
• W4379328966 startingPage "1029" @default.
• W4379328966 abstract "1029 Background: Preclinical evidence suggests that breast cancer with features of genomic instability may upregulate the host antitumor immune response by producing neoantigens through DNA damage and increasing interferon production through the stimulator of interferon genes (STING) pathway. In this study, we evaluated the association between features of genomic instability and immune response in a real-world breast cancer population. Methods: We analyzed retrospective comprehensive genomic and immune profiling (CGIP) results from 529 breast tumors tested in the real-world clinical setting. We defined the HRD phenotype as tumor with any single nucleotide variants (SNV), indels, copy number variations (CNV) or fusions in the following genes: ARID1A, ATM, ATRX, BAP1, BARD1, BLM, BRCA1/2, BRIP1, CHEK1/2, FANCA, MRE11A, NBN, PALB2, RAD50 and RAD51. Otherwise, they were considered HR-proficient (HRP). PD-L1 expression (CPS positive ≥10) and TMB (high ≥10 Mut/Mb) were determined using IHC and DNA sequencing, respectively. mRNA expression signatures of tumor inflammation (TIGS, strong/moderate/weak), cell proliferation (CP, high/moderate/poor) and cancer testis antigen burden (CTAB, high/low) were determined by RNA-sequencing from a 395-gene panel. We used over-representation and proportion analysis using chi-squared test to determine association of HRD to immune correlates. Results: Among 529 cases, the median patient age was 63.2 years (25.5-93.5). The majority of patients were female (519, 98%), and the most common tumor histology was invasive ductal carcinoma (287, 54%). A total of 405 (77%) and 124 (23%) of patients had HRD and HRP phenotypes, respectively. A greater proportion of HRD tumors (16%) had higher TMB compared to HRP (5.6%, p=0.003). HRP tumors showed a relatively low CP index, whereas HRD tumors were associated with a moderate CP index score (p = 0.007). HRD phenotype was associated with a significantly higher proportion of weakly inflamed tumors, as represented by lower TIGS scores (p=0.007). No significant difference in PD-L1 or CTAB was found between HRD and HRP phenotypes. Conclusions: Breast tumors with mutations in the HR genes demonstrated greater TMB and moderate cellular proliferation index of both tumor and immune cells, which suggest susceptibility to immune checkpoint inhibitors. Interestingly, this cohort lacked elevated markers of immune infiltration (TIGS), indicating a mechanism of potential tumor immune evasion. These results suggest that CGIP may allow for more informed treatment decisions in HRD breast cancers. Furthermore, assessment of HR status and immunotherapy susceptibility may support clinical trial selections for therapies targeting the complex interplay of genomic and immune components of breast cancer (e.g., a combination of PARP inhibitor and immunotherapy)." @default.
• W4379328966 created "2023-06-05" @default.
• W4379328966 creator A5003764522 @default.
• W4379328966 creator A5011690650 @default.
• W4379328966 creator A5024077003 @default.
• W4379328966 creator A5026556414 @default.
• W4379328966 creator A5027499943 @default.
• W4379328966 creator A5030901865 @default.
• W4379328966 creator A5037780867 @default.
• W4379328966 creator A5051606936 @default.
• W4379328966 creator A5067217729 @default.
• W4379328966 creator A5067892203 @default.
• W4379328966 creator A5071349192 @default.
• W4379328966 creator A5071642225 @default.
• W4379328966 creator A5075920014 @default.
• W4379328966 creator A5077702152 @default.
• W4379328966 creator A5080700188 @default.
• W4379328966 creator A5081353089 @default.
• W4379328966 date "2023-06-01" @default.
• W4379328966 modified "2023-10-01" @default.
• W4379328966 title "Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP)." @default.
• W4379328966 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1029" @default.
• W4379328966 hasPublicationYear "2023" @default.
• W4379328966 type Work @default.
• W4379328966 citedByCount "0" @default.
• W4379328966 crossrefType "journal-article" @default.
• W4379328966 hasAuthorship W4379328966A5003764522 @default.
• W4379328966 hasAuthorship W4379328966A5011690650 @default.
• W4379328966 hasAuthorship W4379328966A5024077003 @default.
• W4379328966 hasAuthorship W4379328966A5026556414 @default.
• W4379328966 hasAuthorship W4379328966A5027499943 @default.
• W4379328966 hasAuthorship W4379328966A5030901865 @default.
• W4379328966 hasAuthorship W4379328966A5037780867 @default.
• W4379328966 hasAuthorship W4379328966A5051606936 @default.
• W4379328966 hasAuthorship W4379328966A5067217729 @default.
• W4379328966 hasAuthorship W4379328966A5067892203 @default.
• W4379328966 hasAuthorship W4379328966A5071349192 @default.
• W4379328966 hasAuthorship W4379328966A5071642225 @default.
• W4379328966 hasAuthorship W4379328966A5075920014 @default.
• W4379328966 hasAuthorship W4379328966A5077702152 @default.
• W4379328966 hasAuthorship W4379328966A5080700188 @default.
• W4379328966 hasAuthorship W4379328966A5081353089 @default.
• W4379328966 hasConcept C104317684 @default.
• W4379328966 hasConcept C121608353 @default.
• W4379328966 hasConcept C126322002 @default.
• W4379328966 hasConcept C134935766 @default.
• W4379328966 hasConcept C143425029 @default.
• W4379328966 hasConcept C178169997 @default.
• W4379328966 hasConcept C203014093 @default.
• W4379328966 hasConcept C2777701055 @default.
• W4379328966 hasConcept C2778124228 @default.
• W4379328966 hasConcept C2778993383 @default.
• W4379328966 hasConcept C2780851360 @default.
• W4379328966 hasConcept C502942594 @default.
• W4379328966 hasConcept C530470458 @default.
• W4379328966 hasConcept C54355233 @default.
• W4379328966 hasConcept C552990157 @default.
• W4379328966 hasConcept C71924100 @default.
• W4379328966 hasConcept C86803240 @default.
• W4379328966 hasConcept C8891405 @default.
• W4379328966 hasConceptScore W4379328966C104317684 @default.
• W4379328966 hasConceptScore W4379328966C121608353 @default.
• W4379328966 hasConceptScore W4379328966C126322002 @default.
• W4379328966 hasConceptScore W4379328966C134935766 @default.
• W4379328966 hasConceptScore W4379328966C143425029 @default.
• W4379328966 hasConceptScore W4379328966C178169997 @default.
• W4379328966 hasConceptScore W4379328966C203014093 @default.
• W4379328966 hasConceptScore W4379328966C2777701055 @default.
• W4379328966 hasConceptScore W4379328966C2778124228 @default.
• W4379328966 hasConceptScore W4379328966C2778993383 @default.
• W4379328966 hasConceptScore W4379328966C2780851360 @default.
• W4379328966 hasConceptScore W4379328966C502942594 @default.
• W4379328966 hasConceptScore W4379328966C530470458 @default.
• W4379328966 hasConceptScore W4379328966C54355233 @default.
• W4379328966 hasConceptScore W4379328966C552990157 @default.
• W4379328966 hasConceptScore W4379328966C71924100 @default.
• W4379328966 hasConceptScore W4379328966C86803240 @default.
• W4379328966 hasConceptScore W4379328966C8891405 @default.
• W4379328966 hasIssue "16_suppl" @default.
• W4379328966 hasLocation W43793289661 @default.
• W4379328966 hasOpenAccess W4379328966 @default.
• W4379328966 hasPrimaryLocation W43793289661 @default.
• W4379328966 hasRelatedWork W1996150995 @default.
• W4379328966 hasRelatedWork W2023771859 @default.
• W4379328966 hasRelatedWork W2380021556 @default.
• W4379328966 hasRelatedWork W2763883091 @default.
• W4379328966 hasRelatedWork W3009386543 @default.
• W4379328966 hasRelatedWork W3180780036 @default.
• W4379328966 hasRelatedWork W4210960713 @default.
• W4379328966 hasRelatedWork W4291367166 @default.
• W4379328966 hasRelatedWork W4360983034 @default.
• W4379328966 hasRelatedWork W4378715746 @default.
• W4379328966 hasVolume "41" @default.
• W4379328966 isParatext "false" @default.
• W4379328966 isRetracted "false" @default.
• W4379328966 workType "article" @default.